PubMed Health⌕ Search

Biomedical subjects

L Tschopp

Publications and source records attributed to L Tschopp.

24 records · Page 2Linked to original sources
PubMed1977

[Acute myeloid leukaemia in the course of Hodgkin's disease (author's transl)].

Acute myeloid leukaemia occurred in six patients who had been treated for Hodgkin's disease for a number of years. Usually the leukaemia diagnosis was preceded by a striking pancytopenic phase, bone-marrow aspiration being more useful diagnostically than biopsy. Five of these six patients have come under observation in the last eighteen months. This extraordinary frequency of secondary acute myeloid leukaemia once again raises the question of the leukaemogenic effect of intensive radiotherapy and chemotherapy, and also new aspects in the therapeutic management of Hodgkin's disease, especially combined radiotherapy and chemotherapy, as well as long-term maintenance chemotherapy.

Adolescent↗
PubMed1977

[VP 16-213 in combination with endoxan, methotrexate and oncovin as polychemotherapy for bronchogenic carcinoma].

Thirty patients with bronchogenic carcinoma underwent an 8 week course of induction therapy consisting of cyclophosphamide, methotrexate, vincristine, and VP 16-213 (NSC 141 540). Those who achieved objective remission or tumor stabilization were then placed on an intermittent treatment schedule with the same drugs. Of the 30 patients, 17 had an objective response, 5 were unchanged and 8 progressed. Responses were more frequent in anaplastic carcinoma (13/19) than epidermoid or adenocarcinoma (4/11). The toxicity mainly consisted of leukopenia, thrombopenia, alopecia, nausea and vomiting. The implications of these findings in the planning of further chemotherapeutic programs are discussed.

Adenocarcinoma↗
PubMed1976

[First therapeutic experience with cis-platinum(II)diamindichloride (NSC 119875) in metastasizing ovarian and testicular carcinoma].

Ten patients with metastatic testicular or ovarian carcinoma were treated with cis-platinum II diaminedichloride. All had received prior chemotherapy with other agents. A therapeutic effect was seen in 7 cases, though it was of short duration in all instances. The drug proved to be very nephrotoxic and caused marked bone marrow depression. The future of this highly effective cytostatic agent, either with different dosage schedules or in combination with other drugs, is discussed. The possibility of new platinum derivatives with a better therapeutic index is also mentioned.

Adult↗
PubMedDate not supplied

Acute erythroleukemia following chemotherapy for Hodgkin's disease.

A case of erythroleukemia developing in a patient 6.5 years after therapy for Hodgkin's disease (HD) is described. The patient had chemotherapy alone for a stage III B lymphocyte-predominant HD. He received six cycles MOPP-induction therapy followed by a chlorambucil maintenance therapy with procarbazine and prednisone reinforcements. To our knowledge this is the first case of erythroleukemia following HD treated with chemotherapy alone.

Acute Disease↗
PubMedDate not supplied

Combination chemotherapy with VM-26, adriamycin bleomycin, and prednisone as a secondary treatment of malignant lymphoma.

Thirty-eight pretreated patients with Hodgkin's disease (HD) and malignant non-Hodgkin's lymphoma were given combination chemotherapy with VM-26, Adriamycin, bleomycin, and prednisone. Four of 15 evaluable patients with HD achieved a partial remission (PR), with a median duration of 8 months. Of 12 patients with diffuse poorly differentiated lymphocytic lymphoma, one achieved a complete remission (30+ months) and five achieved a PR (median, 6 months). One of three patients with histiocytic lymphoma had a PR of 1.5 months. There was one drug-related death. Five patients developed life-threatening hematologic toxicity. Two HD responders died of acute nonlymphocytic leukemia.

Adult↗